Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.

Abstract

Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). Secnidazole is characterized by potent in vitro antimicrobial activity against BV-associated pathogens, as well as prolonged terminal elimination half-life and systemic exposure. These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clinical trials conducted in the USA. The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.

• Authors: Paul Nyirjesy, Jane R Schwebke
• Journal: Future microbiology (Future Microbiol) Vol. 13 Pg. 507-524 (04 2018) ISSN: 1746-0921 [Electronic] England
• PMID: 29327947 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Metronidazole
• secnidazole

Topics

• Administration, Oral
• Adolescent
• Adult
• Anti-Bacterial Agents (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
• Controlled Clinical Trials as Topic
• Double-Blind Method
• Female
• Gram-Negative Bacteria (drug effects)
• Gram-Positive Bacteria (drug effects)
• Humans
• Metronidazole (administration & dosage, analogs & derivatives, chemistry, pharmacokinetics, therapeutic use)
• Middle Aged
• Multicenter Studies as Topic
• Trichomonas Vaginitis (drug therapy)
• Trichomonas vaginalis (drug effects)
• United States
• Vaginosis, Bacterial (drug therapy)
• Young Adult